Orofacial Pain: Neuropathic and Idiopathic Conditions

Temporomandibular disorders (TMD) dominate the orofacial pain landscape to such an extent that other orofacial pain conditions are frequently overlooked, misdiagnosed, or dismissed as psychogenic. Yet beyond the familiar territory of myofascial pain, internal derangement, and osteoarthritis of the temporomandibular joint lies a heterogeneous group of neuropathic and idiopathic pain disorders that demand entirely different diagnostic approaches and therapeutic strategies. Misdiagnosis of these conditions as TMD or dental pathology leads to unnecessary and ineffective dental treatment, prolonged suffering, and erosion of the therapeutic alliance between patient and clinician. This article reviews the major neuropathic and idiopathic orofacial pain conditions beyond TMD.

Classification of Orofacial Pain

The International Classification of Orofacial Pain (ICOP), first published in 2020, provides a structured taxonomy:

• Nociceptive pain: Pain arising from activation of peripheral nociceptors by actual or threatened tissue damage (dental caries, pulpitis, periodontitis, mucosal ulceration, TMD nociceptive pain)
• Neuropathic pain: Pain caused by a lesion or disease of the somatosensory nervous system (trigeminal neuralgia, postherpetic neuralgia, post-traumatic trigeminal neuropathic pain)
• Nociplastic (idiopathic) pain: Pain arising from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain (persistent idiopathic facial pain, burning mouth syndrome)

The clinical imperative is clear: neuropathic and nociplastic pains do not respond to treatments targeting peripheral nociception—extraction, endodontic therapy, occlusal adjustment, or TMJ surgery—and their misidentification as nociceptive pain drives a cascade of futile and harmful interventions.

Trigeminal Neuralgia

Trigeminal neuralgia (TN), or tic douloureux, is the archetypal neuropathic orofacial pain, characterized by recurrent, unilateral, brief, electric shock-like pains with abrupt onset and termination, limited to the distribution of one or more divisions of the trigeminal nerve.

Clinical Features

• Pain quality: Paroxysmal, stabbing, electric shock-like, shooting, lancinating. Each paroxysm lasts from a fraction of a second to approximately two minutes, with pain-free intervals between attacks that may last minutes to hours.
• Distribution: Unilateral; the maxillary (V2) and mandibular (V3) divisions are most commonly affected (V2 alone ~35%, V3 alone ~15%, V2+V3 ~20%). Isolated ophthalmic (V1) division involvement is rare (<5%). Bilateral involvement occurs in <5% and raises suspicion for multiple sclerosis.
• Triggers: Light mechanical stimulation of a well-defined, often miniscule trigger zone—touching a specific facial point, speaking, chewing, brushing teeth, washing the face, a breeze, or even vibration. The hallmark of TN is the stark contrast between the minimal stimulus and the explosive pain response. Patients learn to avoid touching their trigger zone, sometimes refusing to eat, speak, shave, or brush their teeth on the affected side, resulting in poor oral hygiene, weight loss, and social isolation.
• Refractory period: A characteristic refractory period follows each paroxysm, during which repeated stimulation of the trigger zone does not provoke further pain.

Etiology and Classification

Classical TN: Caused by neurovascular compression of the trigeminal nerve root by an aberrant arterial loop (most commonly the superior cerebellar artery) at the root entry zone near the pons. The pulsatile compression produces focal demyelination, enabling ephaptic cross-talk between adjacent nerve fibers—a light touch signal in a myelinated A-beta fiber crosses to an adjacent nociceptive fiber, producing the explosive pain paroxysm.

Secondary TN: Trigeminal neuralgia attributable to an underlying disease other than neurovascular compression, most commonly multiple sclerosis (demyelinating plaque at the trigeminal root entry zone) or a cerebellopontine angle tumor (vestibular schwannoma, meningioma, epidermoid cyst) compressing the trigeminal nerve. All patients diagnosed with TN should undergo MRI of the brain with high-resolution imaging of the posterior fossa to exclude these secondary causes.

Idiopathic TN: Trigeminal neuralgia in which no neurovascular compression or other cause can be identified on imaging.

Management

Pharmacotherapy (first-line): Carbamazepine (200-1200 mg/day) is the gold standard, producing complete or near-complete pain relief in 70-80% of patients. Oxcarbazepine (600-1800 mg/day) offers comparable efficacy with fewer drug interactions and a more favorable side effect profile. Baseline and periodic monitoring of complete blood count, liver function, and serum sodium (especially with oxcarbazepine) is mandatory. Second-line agents include gabapentin, pregabalin, lamotrigine, and baclofen.

Surgical intervention: Microvascular decompression (MVD) via posterior fossa craniotomy addresses the underlying pathology in classical TN, with long-term success rates of 70-80% at 10 years. Percutaneous ablative procedures (radiofrequency thermocoagulation, glycerol rhizolysis, balloon compression) and stereotactic radiosurgery (Gamma Knife) produce pain relief in 70-90% but with a higher recurrence rate and the trade-off of postoperative sensory loss.

Trigeminal Neuralgia with Concomitant Continuous Pain

Some patients with longstanding TN develop a continuous, burning, aching background pain in the same distribution, superimposed on which the characteristic paroxysms continue to occur. This represents a transition from purely paroxysmal neuropathic pain to a mixed paroxysmal-continuous phenotype that is more difficult to treat. The continuous component responds less to carbamazepine and more to tricyclic antidepressants and gabapentinoids used for continuous neuropathic pain states.

Postherpetic Neuralgia

Postherpetic neuralgia (PHN) is a neuropathic pain persisting for more than 3 months after the resolution of the cutaneous rash of herpes zoster (shingles). When the ophthalmic division (V1) of the trigeminal nerve is involved (herpes zoster ophthalmicus), the risk of PHN is substantial.

Clinical Presentation

• Pain: Constant deep aching or burning pain with superimposed lancinating, electric shock-like pains in the previously affected dermatome. Allodynia—pain produced by normally innocuous stimuli such as light touch or clothing contact—is characteristic.
• Sensory abnormalities: The involved dermatome exhibits sensory loss (hypoesthesia) interspersed with areas of hyperalgesia and allodynia—the "anesthesia dolorosa" paradox of pain in a numb area.
• Scarring: Atrophic, hypopigmented, or hyperpigmented scars remain at the sites of the healed vesicular eruption, marking the dermatomal distribution.

Risk factors: Advanced age (>60 years), severe acute pain during the zoster episode, severe rash, and V1 involvement increase the risk of PHN. The varicella-zoster vaccine (Zostavax, Shingrix) reduces the incidence of herpes zoster by 51-97% and the incidence of PHN by 67-91%, depending on the vaccine formulation and patient age.

Management

Tricyclic antidepressants (amitriptyline, nortriptyline), gabapentinoids (gabapentin, pregabalin), and topical lidocaine 5% patches are first-line agents. High-concentration topical capsaicin 8% patch and opioid analgesics (tramadol) are second-line. Combination therapy targeting different pain mechanisms is often necessary. Treatment should be initiated at low doses and titrated slowly to mitigate side effects, particularly in elderly patients.

Post-Traumatic Trigeminal Neuropathic Pain

Post-traumatic trigeminal neuropathic pain (PTTN) is a chronic neuropathic pain condition resulting from direct injury to one or more branches of the trigeminal nerve. The injury most commonly occurs during dental procedures: third molar extraction (inferior alveolar and lingual nerves), endodontic treatment (chemical injury from extrusion of irrigants or sealers beyond the apex), implant placement (direct mechanical injury or encroachment on the inferior alveolar canal), and orthognathic surgery (sagittal split osteotomy).

Clinical Features

Continuous burning, aching, or throbbing pain in the distribution of the injured nerve, often with superimposed electric shock-like or shooting pains. Sensory testing reveals a combination of negative sensory signs (hypoesthesia, hypoalgesia) and positive sensory signs (allodynia, hyperalgesia). The onset is temporally related to the traumatic event, though a delay of days to weeks before pain onset is not unusual.

Management

Prevention through meticulous surgical technique and preoperative risk assessment is paramount. Once established, PTTN is managed pharmacologically with the same agents used for other neuropathic pain conditions (tricyclic antidepressants, gabapentinoids, serotonin-norepinephrine reuptake inhibitors). Topical medications (lidocaine, capsaicin, clonidine) may provide localized relief without systemic side effects. Neurosurgical interventions—nerve repair (direct neurorrhaphy), nerve grafting, or trigeminal nerve stimulation—are reserved for refractory cases with demonstrated nerve transection or neuroma formation on imaging.

Burning Mouth Syndrome

Burning mouth syndrome (BMS) is an idiopathic, chronic intraoral burning or dysesthetic sensation for which no causative medical or dental pathology can be identified. It predominantly affects postmenopausal women (female-to-male ratio approximately 3-7:1) with a mean age of onset of 55-60 years.

Clinical Features

• Symptoms: Persistent, bilateral oral burning, scalding, or tingling sensation. The tongue (particularly the anterior two-thirds and tip) is the most commonly affected site, followed by the hard palate, lips, and alveolar ridges. The symptoms are typically absent or minimal upon waking, progressively worsening through the day to peak intensity by evening. This diurnal pattern—absent in the morning, maximal in the evening—is a defining feature that distinguishes BMS from other oral pain conditions.
• Associated symptoms: Dysgeusia (persistent bitter, metallic, or altered taste) and xerostomia (subjective dry mouth sensation despite normal salivary flow rates on objective testing) frequently accompany the burning sensation.
• Normal clinical examination: The oral mucosa appears completely normal. The absence of visible mucosal pathology despite the patient's report of severe burning is a defining and diagnostically challenging feature.

Classification

• Primary (idiopathic) BMS: Burning sensation in the absence of any identifiable local or systemic cause. Current evidence suggests that primary BMS is a neuropathic pain condition involving peripheral small-fiber neuropathy of the lingual nerve, central sensitization of trigeminal nociceptive pathways, and altered central pain modulation, with the degeneration of epithelial and subepithelial nerve fibers demonstrated on tongue biopsy immunohistochemistry.
• Secondary BMS: Burning sensation attributable to an identifiable underlying cause. Common causes include nutritional deficiencies (iron, vitamin B12, folic acid, zinc), endocrine disorders (diabetes mellitus, hypothyroidism), xerostomia (medication-induced, Sjogren's syndrome), oral candidiasis, allergic contact stomatitis (dental materials, sodium lauryl sulfate in toothpaste), and gastroesophageal reflux. The diagnosis of primary BMS requires exclusion of all secondary causes through laboratory testing (complete blood count, serum ferritin, vitamin B12, folate, fasting glucose, thyroid function, antinuclear antibodies, anti-Ro/SSA, anti-La/SSB) and clinical examination.

Management

There is no single universally effective treatment for primary BMS. The following interventions have demonstrated efficacy in randomized controlled trials:

• Cognitive behavioral therapy (CBT): The only intervention with Grade A evidence. CBT helps patients reframe pain cognitions, reduce catastrophizing, and develop adaptive coping strategies, resulting in significant improvement in pain intensity and quality of life.
• Clonazepam (topical): Dissolving a 0.5-1 mg clonazepam tablet in the mouth and swishing for 3 minutes, then expectorating (not swallowing), produces local GABA-ergic modulation of peripheral nociceptors. Efficacy has been demonstrated in multiple randomized controlled trials, with minimal systemic absorption and side effects.
• Alpha-lipoic acid: An antioxidant that may address the neuropathic component; meta-analyses show modest but significant benefit over placebo.
• Systemic medications: Low-dose tricyclic antidepressants, gabapentinoids, and selective serotonin reuptake inhibitors are used off-label for refractory cases, though evidence for their efficacy in BMS specifically is limited.

Critical clinical pearl: BMS patients frequently present to the dentist after multiple unsuccessful dental treatments—extractions, endodontic therapy, occlusal adjustments, even full-mouth rehabilitation—performed in the erroneous belief that the burning sensation originates from dental or periodontal pathology. The astute clinician must recognize the normal-appearing mucosa and characteristic symptom profile of BMS and protect the patient from unnecessary and irreversible dental treatment.

Persistent Idiopathic Facial Pain

Persistent idiopathic facial pain (PIFP), previously termed atypical facial pain, is a persistent, poorly localized facial pain that does not fit the diagnostic criteria for any other orofacial pain disorder and has no identifiable underlying cause.

Clinical Features

PIFP is characterized by continuous, dull, aching, or nagging pain that is deep, poorly localized, and does not follow the anatomic distribution of a peripheral nerve or dermatome. The pain is typically unilateral but may cross the midline. It is most commonly felt in the maxilla, periorbital, and perinasal regions. Unlike trigeminal neuralgia, there are no paroxysms, no trigger zones, and no electric shock-like quality. Neurologic examination and imaging (MRI) are normal, distinguishing PIFP from secondary causes. Psychological comorbidity—depression, anxiety, and somatization—is common but should not be invoked to dismiss the pain as "psychogenic." PIFP is a genuine pain condition with neurobiological underpinnings involving central sensitization and altered pain modulation.

Management

Tricyclic antidepressants (amitriptyline, nortriptyline) and SNRIs (duloxetine, venlafaxine) are first-line pharmacotherapy, reflecting the role of descending monoaminergic pain inhibitory pathway dysfunction. Cognitive behavioral therapy and multidisciplinary pain management programs address the psychosocial dimensions. Dental and surgical interventions are contraindicated and frequently worsen the pain by providing additional nociceptive input that reinforces central sensitization.

Diagnostic Approach to Non-TMD Orofacial Pain

The differential diagnosis of orofacial pain requires a structured approach:

1. Is the pain originating from dental or oral mucosal pathology? Clinical examination, percussion, palpation, radiographs, and vitality testing exclude odontogenic pain, periodontal pain, and mucosal disease.
2. Is the pain attributable to TMD? Examination of the masticatory muscles, TMJ range of motion, joint sounds, and provocation testing identifies or excludes TMD.
3. Is the pain neuropathic? The presence of electric shock-like paroxysms with trigger zones (TN), dermatomal distribution with antecedent rash (PHN), or history of nerve trauma (PTTN) suggests neuropathic pain.
4. Is the pain idiopathic? Bilateral burning with normal mucosa and diurnal variation (BMS) or deep, poorly localized continuous pain with normal examination and imaging (PIFP) suggests nociplastic pain.
5. Are there secondary causes? MRI for structural pathology (tumor, multiple sclerosis, vascular compression), laboratory investigation for systemic disease.

Conclusion

The orofacial pain clinician must maintain a broad differential diagnosis that extends beyond TMD to include neuropathic and idiopathic pain conditions. Trigeminal neuralgia, postherpetic neuralgia, post-traumatic trigeminal neuropathic pain, burning mouth syndrome, and persistent idiopathic facial pain each have distinctive clinical profiles, etiologies, and evidence-based treatments. Recognition of these conditions protects the patient from the cascade of unnecessary dental interventions that so often compound the suffering of orofacial pain patients, while directing them toward effective, mechanism-based therapy. The first rule of orofacial pain diagnosis—before any treatment is initiated—is to answer the question: is this nociceptive, neuropathic, or nociplastic pain? The answer determines everything that follows.